Background: Many cancer patients who receive chemotherapy experience adverse drug
effects. Pharmacogenomics (PGx) has promise to personalize chemotherapy drug dosing to …

Prostate cancer (PCa) is the most common cancer affecting men, with increasing global
mortality and morbidity rates. Despite the progress in the diagnosis and treatment of PCa …

Poly (ADP-ribose) polymerase inhibitors (PARPi) are the first clinically approved agents
designed to exploit synthetic lethality. Based on the recent approvals, PARPi became …

Background Among men with metastatic prostate cancer, about 10% have germline
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …

Background Significant racial disparities in prostate cancer incidence and mortality have
been reported between African American Men (AAM), who are at increased risk for prostate …

Historically, genetic testing (and billing) for hereditary cancer risk was essentially performed
gene by gene, with clinicians ordering testing only for the genes most likely to explain a …

Background: Genetic testing, particularly for BRCA1/2, is increasingly important in prostate
cancer (PCa) care, with impact on PCa management and hereditary cancer risk. However …

Simple Summary This review paper seeks to summarize the current literature on the role of
PARP Inhibitors in Advanced Prostate Cancer in tumors with defects in genes associated …

Background Advanced prostate cancer (PC) patients, especially those with metastatic
prostate cancer (mPC), often require complex management pathways. Despite the …

RAB3B is essential for the transportation and secretion within cells. Its increased expression
is linked to the development and progression of various malignancies. However …